KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.Br J CancerPMID 35610366PMC93815812022-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.Ann OncolPMID 35636621无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.Br J CancerPMID 35637412PMC94277792022-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.Clin Lymphoma Myeloma LeukPMID 35643855无 PMCID2022-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.J Clin PsychopharmacolPMID 35652746PMC94267302022 Sep0.98未发现恶性肿瘤人群证据。待处理
Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study.Clin Colorectal CancerPMID 35654691无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.J Thorac OncolPMID 35659580无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.ProstatePMID 35675470无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Support Care CancerPMID 35678882无 PMCID2022-Sep0.95The trial meets most criteria (oncology, human, randomized, Phase III, drug intervention, original result). However, the primary efficacy endpoint is 'proportion of patients achieving complete hematological response at 12 weeks', which is a categorical/binary outcome, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis involving Kaplan-Meier curves or hazard ratios. Therefore, it is excluded.待处理
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.GastroenterologyPMID 35679950无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.Ann OncolPMID 35688358无 PMCID2022-Sep1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).Int J Clin OncolPMID 35723758无 PMCID2022-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).Cancer SciPMID 35754298PMC94593452022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPMID 35780807无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.Ann Intern MedPMID 35785530PMC92587842022-Sep0.98未发现恶性肿瘤人群证据。待处理
Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.Eur UrolPMID 35787935无 PMCID2022-Sep0.45The record is from a Phase III randomized controlled trial in human oncology, but the provided abstract is empty and no keywords or MeSH terms explicitly signal the presence of survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes. Without abstract content or other data confirming such outcomes, eligibility cannot be determined.待处理
HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis.Radiother OncolPMID 35817323无 PMCID2022-Sep0.95The record is an interim safety and dosimetry report from a definitive Phase III RCT in oncology but lacks the required efficacy outcomes (e.g., survival, progression, recurrence) for KM digitization. Therefore, it is excluded.待处理
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?Mol Diagn TherPMID 35841457PMC94110882022-Sep0.90The record describes a viewpoint/commentary article analyzing the failure of a Phase III trial for mongersen in Crohn's disease (non-oncology). It is not an original report of a primary or secondary efficacy result from a randomized trial with a time-to-event endpoint (OS, PFS, etc.).待处理
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.Gynecol OncolPMID 35851489无 PMCID2022-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.LeukemiaPMID 35869266PMC94179852022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.Ann HematolPMID 35869984PMC93757562022-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.Lancet OncolPMID 35908558无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes EndocrinolPMID 35914542无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.Lancet Diabetes EndocrinolPMID 35914543无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.Adv TherPMID 35917059PMC94024872022-Sep0.98未发现恶性肿瘤人群证据。待处理
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.Lung CancerPMID 35917647无 PMCID2022-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.Clin J Am Soc NephrolPMID 35918106PMC96250962022-Sep0.98未发现恶性肿瘤人群证据。待处理
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.Am J Clin DermatolPMID 35934770PMC94647492022-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.Lancet Glob HealthPMID 35961356PMC93802572022-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet NeurolPMID 35963261无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.Lancet OncolPMID 35964621无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.Nat MedPMID 35995953PMC94998542022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.JACC Heart FailPMID 36049817无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet OncolPMID 36055304无 PMCID2022-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.Lancet HaematolPMID 36055332无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever.Clin Exp RheumatolPMID 36106542无 PMCID2022-Sep0.98未发现恶性肿瘤人群证据。待处理
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.Clin Infect DisPMID 34940806PMC94271372022-Aug-310.98未发现恶性肿瘤人群证据。待处理
Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets.J Pediatr Endocrinol MetabPMID 35700440无 PMCID2022-Aug-260.98未发现恶性肿瘤人群证据。待处理
One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.VaccinePMID 35933278无 PMCID2022-Aug-260.98未发现恶性肿瘤人群证据。待处理
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.Orphanet J Rare DisPMID 36028858PMC94193982022-Aug-260.98未发现恶性肿瘤人群证据。待处理
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.J Antimicrob ChemotherPMID 35762503无 PMCID2022-Aug-250.98未发现恶性肿瘤人群证据。待处理
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.N Engl J MedPMID 36001711无 PMCID2022-Aug-250.98未发现恶性肿瘤人群证据。待处理
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.N Engl J MedPMID 36001712无 PMCID2022-Aug-250.99The study is a Phase 3 randomized trial of a drug (olokizumab) in rheumatoid arthritis, which is not an oncology indication. The primary endpoint is an ACR20 response, a categorical/ordinal outcome at a fixed time point, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier or hazard ratio results are reported.待处理
Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.J Infect DisPMID 33351072PMC94004112022-Aug-240.98未发现恶性肿瘤人群证据。待处理
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.Clin Infect DisPMID 34537835PMC94026262022-Aug-240.98未发现恶性肿瘤人群证据。待处理
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.BMC CancerPMID 35999527PMC94002872022-Aug-240.98未发现恶性肿瘤人群证据。待处理
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.JAMAPMID 35997729PMC93998662022-Aug-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).BMC CancerPMID 35999521PMC94002972022-Aug-230.70The study is a Phase III randomized oncology trial with planned OS and DFS endpoints, but it is a protocol without results. Furthermore, the intervention (perioperative corticosteroid flash dose) is a supportive care measure, not a standard systemic drug therapy for the cancer, and the primary endpoint is a safety/morbidity outcome.待处理
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.Nat CommunPMID 35995785PMC93953682022-Aug-220.98未发现恶性肿瘤人群证据。待处理
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.N Engl J MedPMID 36070710PMC99459222022-Aug-180.98未发现恶性肿瘤人群证据。待处理